…And Amgen Makes Three: Another Ustekinumab Biosimilar Gets Go-Ahead In EU
Third Stelara Rival, Wezenla, Receives Positive Opinion From EMA’s CHMP In April Meeting
At the latest meeting of the EMA’s CHMP committee, the agency recommended that Amgen be granted a third European marketing authorization for a Stelara biosimilar.
